Plancorp LLC Buys 10,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Plancorp LLC increased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 12.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,584 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. Plancorp LLC’s holdings in Recursion Pharmaceuticals were worth $592,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of RXRX. State Street Corp increased its stake in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares in the last quarter. Institute for Wealth Management LLC. purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $3,928,000. Platinum Investment Management Ltd. grew its position in Recursion Pharmaceuticals by 293.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company’s stock valued at $4,955,000 after purchasing an additional 546,929 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Recursion Pharmaceuticals by 17.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock valued at $15,372,000 after purchasing an additional 333,323 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $6.68 on Friday. The firm’s 50-day moving average price is $7.47 and its 200-day moving average price is $7.00. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.69 billion, a PE ratio of -4.37 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s revenue was down 57.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.42) EPS. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.